Adamis Pharmaceuticals Corporation (ADMP) Closes at $0.96, Underpriced by 71.51%

Publicly-traded company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) had a closing price of $0.96 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $3.37, this means that the stock is underpriced by 71.51%. In the past 52 weeks the company’s stock price has moved within the range of $0.48 to $3.29.

This particular stock’s 5-day moving average is 0.80, its 20-day moving average is 0.66 and its 100-day moving average is 0.95. Adamis Pharmaceuticals Corporation (ADMP) currently has 67.85M shares outstanding, which means that its market capitalization is $65.14M.

The Details: Adamis Pharmaceuticals Corporation (ADMP) Financial Health

We can also see what the current Return on Assets is for the company, which is a percentage that lets us know how well it is utilizing its net assets to turn a profit. The lower the percentage, the worse the company is making use of its assets. At the moment, Adamis Pharmaceuticals Corporation Return on Assets is -67.10%.

What Does Wall Street Say about Company?

When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for ADMP is Buy. Out of 3 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 0 rated it hold, and 2 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for Adamis Pharmaceuticals Corporation (ADMP) was a Overweight – from a survey of 4 analysts. Of the analysts who provided ratings, 1 rated the company a Hold, 0 rated it a Sell, 1 rated it an overweight, 0 rated it an underweight, and 2 rated it a Buy.

Understanding Profitability at Adamis Pharmaceuticals Corporation (ADMP)

Checking out a public company’s Earnings per Share (EPS) is a smart way of assessing its profitability. In the most recent financial results released by Adamis Pharmaceuticals Corporation, for the quarter ending on 09/2019, the company posted EPS of -0.06. The average estimate of Wall Street analysts had projected -0.05.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.10, compared to -0.21 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 2 analysts is 6.37M – compared to 3.83M posted in the year-ago period.